Advisory Committee Review Expected Prior To Tysabri Market Re-Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan expect Tysabri will be subject to an FDA advisory committee review before the multiple sclerosis therapy is allowed back on the market
You may also be interested in...
Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program
The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.
Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program
The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.